Company name: Ladd Porter (Beijing) Biotechnology Co., Ltd.
Contact: Zhang Wei
Mobile phone: 18101288748
Address: room 2071, 2 floor, 5 building, No. 5 hospital, Beijing, Chaoyang District.
Gyros’ automated nanoliter-scale immunoassay platformsGyrolab xP workstationGyrolab workstation utilizes the microfluidic technology to replace traditional methods for biological macromolecular drug research and immunology experiments of different stage such as R&D, preclinical, clinical and manufactural stages. It has the advantages of high speed, low sample volume, high throughput, wide detection range, low matrix interference, high sensitivity, good accuracy and precision, good repeatability and full automation. It has become the major macromolecular drug research and development platform for the world's leading well-known pharmaceutical companies.
Gyros Protein Technologies (formerly Gyros
AB) is the world leader in utilization of microfluidic technologies to
miniaturize and automate immunoassays. Gyrolab immunoassay platforms
increase productivity and efficiency during development of
biotherapeutics and vaccines, saving time, labor and sample. Major
biopharmaceutical companies and their service providers utilize Gyrolab
platforms to boost time-critical workflows and meet increasingly
stringent regulatory demands.
Whether you need to accelerate assay development for preclinical R&D, facilitate upstream and downstream bioprocessing or meet critical data and time requirements for regulated bioanalysis, Gyros will put a new spin on what’s possible in your laboratory. Using nanoliter microfluidics, Gyros’ flow-through technology simplifies assay workflows by eliminating incubations and shortening run times to produce reliable data exhibiting 3- to 4-log dynamic range and minimal matrix interference.
Fig 1. CD with technology of nanoliter microfluidics
Time Saving: Analyze one CD in one hour, develop new analytical method in several days rather in several weeks.
Low Sample Volume: Utilize technology of nanoliter microfluidics, one mouse for one PK curve, reduce animal usage in preclinical studies.
High Throughput: Generate up to 96/112 high quality data points per CD, run five CD in one batch.
Broad Detection Range: Lower LLOQ and higher ULOQ, suitable for samples of different concentration.
Low Matrix Interference: Suitable for almost any samples, reduce MRD to 1/2 of original data.
Automation: Run automatically for loading samples, loading reagents, washing and detecting, avoid the personal error, reduce CV, can run unattendedly overnight and increase the throughput.
High Sensitivity: pg/mL level sensitivity, suitable for sample of low concentration.
High Precision and Good Repetitiveness: The results is consistent between different researchers, laboratories and companies. Increase the success rate and reduce number of replication.
(1) Pharmacokinetics (PK); Toxicokinetics (TK);
(2) Pharmacodynamics (PD); Biomarker Monitoring;
(3) Immunogenicity; ADA Study;
(4) Product Qualification (IgG Titer) in Bioprocessing;
(5) Impurity Testing (HCP, Protein A) in Bioprocessing;
(6) Affinity Detection and Vaccine Research.
Evaluator, the software of Gyrolab xP
workstation, supports automatic curve fitting, parameters and results
output and support results output to LIMS system. This software is also
designed for 21 CFR part 11 compliance.
These features and advantages liberate the
experimenter's hands, allowing the experimenter to develop the method
with the least amount of samples in the shortest possible time, and get
the best data from experiments such as methods validation and sample
testing. This allows faster and easier access to data that can be used
for decision-making, thereby advancing drug discovery to the next step
and listing as soon as possible.
These advantages make Gyrolab platform
become the major large molecule drug research platform for the world's
major well-known pharmaceutical companies and CROs, including Pfizer,
Novartis, Amgen, AstraZeneca, Roche, Sanofi, Eli Lilly, etc., will
become one of the mainstream equipments for large molecule drug
development in the future. If you wish to keep up with the world's
mainstream technology trend, please come to understand this strong
Ladd Bert (Beijing) biology
Address: Ladd Porter (Beijing) Biotechnology Co., Ltd.
Copyright: Ladd Porter (Beijing) Biotechnology Co., Ltd.